00013 HUTCHMED
- 33.550
- +2.300+7.36%
HUTCHMED News
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended September 30, 2024
HUTCHMED: HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended August 31, 2024
HUTCHMED: Total Voting Rights
HUTCHMED: HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
HUTCHMED: TR-1: Standard form for notification of major holdings
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
HUTCHMED: Notification letter to non-registered shareholders and reply form: Notice of Publication of 2024 Interim Report
HUTCHMED: Notification letter to registered shareholders and reply form: Notice of Publication of 2024 Interim Report
HUTCHMED: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended July 31, 2024
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended June 30, 2024
HUTCHMED: Filing of Form F-3
HUTCHMED: Blocklisting Six Monthly Return
HUTCHMED: Total Voting Rights
HUTCHMED: VOLUNTARY ANNOUNCEMENT - Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
HUTCHMED: HUTCHMED Announces European Commission Approval for FRUZAQLA (fruquintinib) Received by Takeda
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
Analysis
Price Target
No Data
No Data